BRIEF-Alto Neuroscience Announces Completion Of Enrollment In Phase 2 Proof-Of-Concept Study Of Alto-101
Reuters
Yesterday
BRIEF-Alto Neuroscience Announces Completion Of Enrollment In Phase 2 Proof-Of-Concept Study Of Alto-101
Feb 13 (Reuters) - Alto Neuroscience Inc ANRO.N:
ALTO NEUROSCIENCE ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 PROOF-OF-CONCEPT STUDY OF ALTO-101 IN COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA
Source text: ID:nBwblbtfra
Further company coverage: ANRO.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.